New hope for teens with severe eczema: drug CM310 shows promise in phase 3 trial
NCT ID NCT06495229
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study tests a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The goal is to see if the drug is safe and helps clear the skin. Participants receive the drug and are monitored for side effects and improvements in eczema severity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.